Mandate

Vinge advises FSN Capital L.P. II et al. on divestment of the CTEK/Creator Group

June 09, 2011

Vinge is advising FSN Capital L.P. II et al. in connection with the divestment of the CTEK/Creator Group to Altor Fund III.

The CTEK/Creator group is the world’s premier manufacturer of advanced battery chargers, sold under inter alia the "CTEK" brand, and a provider of consulting services related to product development under the “Creator” brand. CTEK is, in addition to sales under its own brand, delivering battery chargers to well renowned brands such as Rolls Royce, Ferrari, Porsche, Bentley, Mercedes-Benz, BMW, Lexus, Lamborghini, Alfa Romeo, Audi, Corvette, Maserati, Scania and Yamaha.

Since the investment by FSN Capital L.P. II in April 2008, CTEK has experienced largely increased sales volumes as well as a largely increased EBITDA despite having made significant investments in sales & marketing, R&D and the overall organization.

Closing of the transaction is subject to applicable competition law approvals.

The Vinge team advising FSN Capital L.P. et al. includes partners Bo Adrianzon and Johan Göthberg and inter alia associates Johan Steen, Carolina Walther and Ulrich Ziche.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026